Role of Autolysins in the Killing of Bacteria by Some Bactericidal Antibiotics H

Total Page:16

File Type:pdf, Size:1020Kb

Role of Autolysins in the Killing of Bacteria by Some Bactericidal Antibiotics H JOURNAL OF BACTERIOLOGY, Dec. 1971, p. 1235-1243 Vol. 108, No. 3 Copyright 0 1971 American Society for Microbiology Printed in U.S.A. Role of Autolysins in the Killing of Bacteria by Some Bactericidal Antibiotics H. J. ROGERS AND C. W. FORSBERG National Institute for Medical Research, Mill Hill, London, N. W.7, England Received for publication 7 June 1971 The rapid lysis of Bacillus licheniformis NCTC 6346 and B. sublilis 168 trp caused by vancomycin and D-cycloserine can be inhibited by stopping protein syn- thesis. Protein synthesis must be stopped for more than one doubling time of the cells before addition of wall inhibitors. Poorly lytic mutants (lyt-) of B. licheni- formis required 10 to 20 times the concentration of vancomycin or cycloserine to be added to growing cultures to cause even slow lysis. At lower concentrations growth of the mutants is stopped, but the bacteria remain fully viable. Sensitivity of mucopep- tide synthesis to vancomycin is the same in both mutants and parent. Sensitivity to the action of D-cycloserine is slightly less in the mutant than in the parent. The penicillins and other antibiotics which in- tide synthesis has now been examined upon auto- hibit the biosynthesis of the cell walls of bacteria lysin-deficient mutants isolated from a strain of may ultimately kill sensitive microorganisms Bacillus licheniformis. Cell walls of these mu- because the autolytic enzymes continue to be tants autolyse only very slowly; therefore the formed and destroy more mucopeptide than can strains have been called lyt- (2). It will be shown be made (17, 24). The wall becomes too weak to that these mutants are relatively resistant to the restrain the osmotic forces within the cells, and bactericidal action of antibiotics such as cyclo- even if cell lysis is not apparent the membranes serine and vancomycin, although of course their are damaged. This hypothesis (17) was originally growth is stopped. In other words, the antibiotics formulated on the basis of the well known phe- become bacteriostatic rather than bactericidal. nomenon that chloramphenicol in the presence of the penicillins is able to prevent the death of MATERIALS AND METHODS some microorganisms (5, 16). Chloramphenicol Microorganisms. The parent was B. licheniformis added shortly after methicillin or benzylpenicillin his, isolated from NCTC 6346 in this department by prevented the lysis of Staphylococcus aureus (17). Moyra McConnell. The lytic-deficient mutants were As the concentration of methicillin was in- isolated as previously described (2). Both the parent creased in the presence of a constant amount of and lyt-3 were kept as spore suspensions; the re- chloramphenicol, a point was reached at which mainder of the mutants were maintained on nutrient mucopeptide synthesis and breakdown were ex- agar plates. Some experiments were also done with B. subliis 168 trp, which was kept in a spore suspension. actly balanced. At higher penicillin concentra- In all cases, an overnight shaken culture was grown in tions, when mucopeptide biosynthesis was more Spizizen salts medium (19) supplemented by 100 ,gg of completely inhibited, there was loss of mucopep- histidine per ml or 20 gg of tryptophan per ml and tide, and eventually lysis occurred. This was pre- 0.3% sodium glutamate contained in a flask five times sumably due to autolysin already present in the the volume of the medium and fitted with a side arm. bacteria at the time of addition of the chloram- This was then inoculated at such a rate as to give an phenicol which stopped protein biosynthesis. optical density of 0.07 to 0.10. Incubation was con- Further evidence in favor of the role of the tinued at 35 C with shaking, until the density reached lytic enzymes in killing microorganisms has been 0.200 to 0.300. At this point the culture was divided into 20-ml amounts and placed in similarly designed produced from the effect of penicillin, cycloser- flasks containing the necessary amounts of antibiotics. ine, and phosphonomycin on pneumococci (24). The extinction of the cultures at 675 nm was measured When the choline normally present in the walls every 20 min by running part of the cultures into the of these organisms is replaced by ethanolamine, side arms and using a Unicam SP-600 spectro- the walls become resistant to the action of the photometer; the readings were corrected by the so- autolysin (23), and the bacteria are killed much called AOD adjustment of Toennies (22). less readily by the antibiotics. Antibiotics. Chloramphenicol was from Parke-Davis, The action of antibiotics that inhibit mucopep- Hounslow, Middlesex, England; vancomycin was from 1235 1236 ROGERS AND FORSBERG J. BACTERIOL. Eli Lilly & Co., Indianapolis, Ind., U.S.A., cycloserine tical densities were read at 450 nm in a Unicam SP- from the Sigma London Chemical Co., London, 600 spectrophotometer. S.W.6, England, and methicillin from Beecham's Re- search Laboratories, Brentford, Middlesex, England. RESULTS Measurement of mucopeptide synthesis. Cultures in the medium already described were allowed to reach an Effect of vancomycin and cyloserine on the par- extinction value of about 0.200. ent, B. licheniformis 6346 his-. B. licheniformis At this time 50 yg of chloramphenicol per ml was 6346 is particularly prone to lysis when the cells added. After a further 30 min of incubation, 2.0 are harvested and suspended in buffer. When iuCi/ml of [U- "Cjglucose and the required concentra- they were growing rapidly in casein hydrolysate tion of either vancomycin or cycloserine were added. medium containing glucose, it proved almost im- Samples were then taken at intervals into enough tri- possible to prepare and work with suspensions of chloroacetic acid to give a concentration of 5%. Vol- the bacteria. Earlier work (6, 11, 12), as well as umes (0.1 ml) of these samples were then filtered onto glass fiber discs which were washed with 5% trichloro- our own, suggests that this autolysis results from acetic acid containing 1 mg of glucose per ml and then the changes during the anaerobiosis suffered by successively heated with 5% trichloroacetic acid at 90 the cells during harvesting and resuspension of C for 6 min, washed with 0.1 M Na-K phosphate buffer the cell paste. Figure I shows that growth of aer- (pH 7.5), incubated for 7 hr with 2 ml of a solution of ated exponentially-growing cultures can be I mg of crystallised trypsin per ml in 0.1 M Na-K phos- stopped by chloramphenicol without lysis; a slow phate buffer (pH 7.5), and finally washed with absolute increase in extinction continues. This increase, alcohol and ether. The discs were dried for 1 hr at 105 like that in staphylococci (7, 16) and B. subtilis C. The radioactivity they contained was estimated by (4), is largely due to the increase that takes place immersion in scintillation fluid and counting with a Packard counter. More than 2,000 counts above back- in the amount of wall material. The addition to ground were collected. This method for measuring the cultures of vancomycin above a concentra- mucopeptide synthesis was designed by I. G. Mathison tion of 0.25 ,ug/ml, or cycloserine above a con- of this institute. In the presence of chloramphenicol, it centration of 5 ,ug/ml, led to rapid and almost gives results which agree within i5 to 10% with those from the more orthodox Park and Hancock (13) method for mucopeptide isolation. The reason for adding chlor- amphenicol to the cultures first was to avoid the mas- sive lysis which otherwise occurred with the parent strain when vancomycin or cycloserine was added (see below). Separate experiments showed that chlor- amphenicol did not affect the rate of mucopeptide syn- thesis by either the parent or the mutant bacteria. Preparation of walls containing autolysin. Cultures (1 liter in 5-liter flasks) in the logarithmic phase of growth (0.25 to 0.30 mg/ml), in Spizizen's minimal medium supplemented with 0.3% glutamate, were har- vested rapidly by centrifugation at room temperature. They were washed once in 0.1 volume of cold water (4 C). All subsequent operations were performed at 4 C. The cells in water (10 to 20 mg/ml in 25 ml of water) were disrupted in a Braun tissue homogenizer by shaking with 20 ml of no. 12 Ballotini beads for 3.5 min with cooling by vaporization of CO2. The dis- rupted cell suspensions were filtered through a no. 2 sintered glass filter to remove the glass beads and cen- trifuged at 1,000 x g for 10 min to remove any re- sidual whole cells. The walls were then sedimented by centrifugation at 36,000 x g for 20 min and washed five times in water. The cell walls were lyophilized and stored at -5 C. There was no apparent difference in the rate of autolysis of fresh and lyophilized walls of either B. subtilis or B. licheniformis. Cell wall autolysis. A cell wall suspension (1.0 ml at 2 mg/ml) in water was added to matched tubes im- Hours mersed in an ice bath. Sodium carbonate buffer (1 ml FIG. 1. Effect of chloramphenicol (50 ,g/ml) and of 0.2 ionic strength and pH 9.5) and water (2 ml) of various concentrations of vancomycin and D-cyclo- were added. The final turbidity was 0.30 to 0.45 optical serine when added to exponentially growing cultures of density units. The tubes were placed in a water bath B. licheniformis NCTC 6346 his. Antibiotics were maintained at 35 C and removed at intervals. The op- added at zero time on the graph. VOL.
Recommended publications
  • The Ligand-Specific Co-Receptor Function of CD44 for Receptor
    The ligand-specific co-receptor function of CD44 for receptor tyrosine kinases Zur Erlangung des akademischen Grades eines DOKTORS DER NATURWISSENSCHAFTEN (Dr. rer. nat.) Fakultät für Chemie und Biowissenschaften Karlsruher Institut für Technologie (KIT) - Universitätsbereich genehmigte DISSERTATION von Christian Jung aus Karlsruhe Dekan: Prof. Dr. Martin Bastmeyer Referent: PD Dr. Véronique Orian-Rousseau Korreferent: Prof. Dr. Doris Wedlich Tag der mündlichen Prüfung: 18.4.2012 I Ich versichere, dass ich meine Arbeit selbständig angefertigt und keine anderen als die angegebenen Quellen und Hilfsmittel benutzt, sowie die wörtlich oder inhaltlich übernommenen Stellen als solche kenntlich gemacht und die Satzung der Universität Karlsruhe (TH) zur Sicherung guter wissenschaftlicher Praxis in der jeweils gültigen Fassung beachtet habe. Christian Jung, März 2012 II Zusammenfassung Listeria monocytogenes, ein gram-positives Bakterium, verursacht die Krankheit Listeriose. Eine Möglichkeit, wie L.monocytogenes Wirbeltierzellen infizieren kann, ist das Binden des Bakteriums an die Rezeportyrosinkinase (RTK) Met auf der Wirtszelle durch das bakterielle Protein InlB. Dieses Binden führt zur Aktivierung von Met und schließlich zur Aufnahme in die Zelle. Der erste Teil meine Doktorarbeit zeigt, dass die Infektion von nicht-phagozytotischen Zellen mittels InlB zusätzlich vom Ko-Rezeptor CD44v6 abhängig ist. Desweiteren kann diese bakterielle Infektion mit einem CD44v6-Peptid blockiert werden. Zusätzlich zu der Ko-Rezeptorfunktion von CD44v6 für InlB und Met, die ich gezeigt habe, wurde CD44v6 bereits als Ko-Rezeptor für die Induktion von Met und VEGFR- 2 durch ihre authentischen Liganden HGF and VEGF-A identifiziert. Im zweiten und Hauptteil meiner Doktorarbeit habe ich untersucht, ob diese Ko-Rezeptorfunktion von CD44v6 spezifisch von den Liganden, den Rezeptoren oder beiden bestimmt wird.
    [Show full text]
  • In Vivo Dual RNA-Seq Analysis Reveals the Basis for Differential Tissue Tropism of Clinical Isolates of Streptococcus Pneumoniae
    In Vivo Dual RNA-Seq Analysis Reveals the Basis for Differential Tissue Tropism of Clinical Isolates of Streptococcus pneumoniae Vikrant Minhas,1,4 Rieza Aprianto,2,4 Lauren J. McAllister,1 Hui Wang,1 Shannon C. David,1 Kimberley T. McLean,1 Iain Comerford,3 Shaun R. McColl,3 James C. Paton,1,5,6,* Jan-Willem Veening,2,5 and Claudia Trappetti,1,5 Supplementary Information Supplementary Table 1. Pneumococcal differential gene expression in the lungs 6 h post-infection, 9-47-Ear vs 9-47M. Genes with fold change (FC) greater than 2 and p < 0.05 are shown. FC values highlighted in blue = upregulated in 9-47-Ear, while values highlighted in red = upregulated in 9- 47M. Locus tag in 9-47- Product padj FC Ear Sp947_chr_00844 Sialidase B 3.08E-10 313.9807 Sp947_chr_02077 hypothetical protein 4.46E-10 306.9412 Sp947_chr_00842 Sodium/glucose cotransporter 2.22E-09 243.4822 Sp947_chr_00841 N-acetylneuraminate lyase 4.53E-09 227.7963 scyllo-inositol 2-dehydrogenase Sp947_chr_00845 (NAD(+)) 4.36E-09 221.051 Sp947_chr_00848 hypothetical protein 1.19E-08 202.7867 V-type sodium ATPase catalytic subunit Sp947_chr_00853 A 1.29E-06 100.5411 Sp947_chr_00846 Beta-glucoside kinase 3.42E-06 98.18951 Sp947_chr_00855 V-type sodium ATPase subunit D 8.34E-06 85.94879 Sp947_chr_00851 V-type sodium ATPase subunit C 2.50E-05 72.46612 Sp947_chr_00843 hypothetical protein 2.17E-05 65.97758 Sp947_chr_00839 HTH-type transcriptional regulator RpiR 3.09E-05 61.28171 Sp947_chr_00854 V-type sodium ATPase subunit B 1.32E-06 50.86992 Sp947_chr_00120 hypothetical protein 3.00E-04
    [Show full text]
  • Investigation of Peptidyl-Prolyl Cis/Trans Isomerases in the Virulence of Staphylococcus
    Investigation of Peptidyl-prolyl cis/trans isomerases in the virulence of Staphylococcus aureus A Dissertation presented to the faculty of the College of Arts and Sciences of Ohio University In partial fulfillment of the requirements for the degree Doctor of Philosophy Rebecca A. Keogh August 2020 © 2020 Rebecca A. Keogh. All Rights Reserved. 2 This Dissertation titled Investigation of Peptidyl-prolyl cis/trans isomerases in the virulence of Staphylococcus aureus by REBECCA A. KEOGH has been approved for the Department of Biological Sciences and the College of Arts and Sciences by Ronan K. Carroll Assistant Professor of Biological Sciences Florenz Plassmann Dean, College of Arts and Sciences 3 ABSTRACT REBECCA A. KEOGH, Doctorate of Philosophy, August 2020, Biological Sciences Investigation of peptidyl-prolyl cis/trans isomerases in the virulence of Staphylococcus aureus Director of Dissertation: Ronan K. Carroll Staphylococcus aureus is a leading cause of both hospital and community- associated infections that can manifest in a wide range of diseases. These diseases range in severity from minor skin and soft tissue infections to life-threatening sepsis, endocarditis and meningitis. Of rising concern is the prevalence of antibiotic resistant S. aureus strains in the population, and the lack of new antibiotics being developed to treat them. A greater understanding of the ability of S. aureus to cause infection is crucial to better inform treatments and combat these antibiotic resistant superbugs. The ability of S. aureus to cause such diverse infections can be attributed to the arsenal of virulence factors produced by the bacterium that work to both evade the human immune system and assist in pathogenesis.
    [Show full text]
  • Zinforo, INN Ceftaroline Fosamil
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Zinforo 600 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains ceftaroline fosamil acetic acid solvate monohydrate equivalent to 600 mg ceftaroline fosamil. After reconstitution, 1 ml of the solution contains 30 mg of ceftaroline fosamil. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. A pale yellowish-white to light yellow powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Zinforo is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): • Complicated skin and soft tissue infections (cSSTI) • Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Posology For the treatment of cSSTI and CAP, the recommended dose is 600 mg administered every 12 hours by intravenous infusion over 60 minutes in patients aged 18 years or older. The recommended treatment duration for cSSTI is 5 to 14 days and the recommended duration of treatment for CAP is 5 to 7 days. Special populations Elderly patients (≥ 65 years) No dosage adjustment is required for the elderly with creatinine clearance values > 50 ml/min (see section 5.2). Renal impairment The dose should be adjusted when creatinine clearance (CrCL) is ≤ 50 ml/min, as shown below (see sections 4.4 and 5.2). Creatinine clearance Dosage regimen Frequency (ml/min) > 30 to ≤ 50 400 mg intravenously (over 60 minutes) every 12 hours 2 There is insufficient data to make specific dosage adjustment recommendations for patients with severe renal impairment (CrCL ≤ 30 ml/min) and end-stage renal disease (ESRD), including patients undergoing haemodialysis (see section 4.4).
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Augmentin 125 mg/31.25 mg/5 ml powder for oral suspension Augmentin 250 mg/62.5 mg/5 ml powder for oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 25 mg amoxicillin and potassium clavulanate equivalent to 6.25 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. When reconstituted, every ml of oral suspension contains amoxicillin trihydrate equivalent to 50 mg amoxicillin and potassium clavulanate equivalent to 12.5 mg of clavulanic acid. Excipients with known effect Every ml of oral suspension contains 2.5 mg aspartame (E951). The flavouring in Augmentin contains maltodextrin (glucose) (see section 4.4). This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium- free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for oral suspension. Off-white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Augmentin is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1): • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis • Pyelonephritis 2 • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis • Bone and joint infections, in particular osteomyelitis.
    [Show full text]
  • Australian Public Assessment Refport for Ceftaroline Fosamil (Zinforo)
    Australian Public Assessment Report for ceftaroline fosamil Proprietary Product Name: Zinforo Sponsor: AstraZeneca Pty Ltd May 2013 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. • An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Novel Therapeutic Interventions Towards Improved Management of Septic Arthritis Jian Wang1* and Liucai Wang2
    Wang and Wang BMC Musculoskeletal Disorders (2021) 22:530 https://doi.org/10.1186/s12891-021-04383-6 REVIEW Open Access Novel therapeutic interventions towards improved management of septic arthritis Jian Wang1* and Liucai Wang2 Abstract Septic arthritis (SA) represents a medical emergency that needs immediate diagnosis and urgent treatment. Despite aggressive treatment and rapid diagnosis of the causative agent, the mortality and lifelong disability, associated with septic arthritis remain high as close to 11%. Moreover, with the rise in drug resistance, the rates of failure of conventional antibiotic therapy have also increased. Among the etiological agents frequently isolated from cases of septic arthritis, Staphylococcus aureus emerges as a dominating pathogen, and to worsen, the rise in methicillin- resistant S. aureus (MRSA) isolates in bone and joint infections is worrisome. MRSA associated cases of septic arthritis exhibit higher mortality, longer hospital stay, and higher treatment failure with poorer clinical outcomes as compared to cases caused by the sensitive strain i.e methicillin-sensitive S. aureus (MSSA). In addition to this, equal or even greater damage is imposed by the exacerbated immune response mounted by the patient’s body in a futile attempt to eradicate the bacteria. The antibiotic therapy may not be sufficient enough to control the progression of damage to the joint involved thus, adding to higher mortality and disability rates despite the prompt and timely start of treatment. This situation implies that efforts and focus towards studying/ understanding new strategies for improved management of sepsis arthritis is prudent and worth exploring. The review article aims to give a complete insight into the new therapeutic approaches studied by workers lately in this field.
    [Show full text]
  • DICLOXACILLIN MYLAN Dicloxacillin Sodium Capsules
    AUSTRALIAN PRODUCT INFORMATION DICLOXACILLIN MYLAN Dicloxacillin sodium capsules 1 NAME OF THE MEDICINE Dicloxacillin (as dicloxacillin sodium) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains dicloxacillin sodium equivalent to 250 mg or 500 mg dicloxacillin as the active ingredient. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM DICLOXACILLIN : Dicloxacillin 250 mg capsule: Size 2 capsule with white opaque body and cap, MYLAN 250 marked ‘DX’ on the cap and ‘250’ on the body in black DICLOXACILLIN : Dicloxacillin 500 mg capsule: Size 0 capsule with white opaque body and cap, MYLAN 500 marked ‘DX’ on the cap and ‘500’ on the body in black 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of confirmed or suspected staphylococcal and other Gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia). Bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. Dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. Dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin. Important Note: When it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin. 4.2 DOSE AND METHOD OF ADMINISTRATION Microbiological studies to determine the causative organism and their susceptibility to the penicillinase resistant penicillins should be performed.
    [Show full text]
  • 2011/109440 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . 9 September 2011 (09.09.2011) 2011/109440 Al (51) International Patent Classification: [CH/CH]; Chemin Des Chevreuils 1, 1188 Gimel (CH). C12Q 1/68 (2006.01) G01N 33/53 (2006.01) HOLTERMAN, Daniel [US/US]; 14465 North 14th St., Phoenix, AZ 85022 (US). (21) International Application Number: PCT/US201 1/026750 (74) Agent: AKHAVAN, Ramin; Caris Life Sciences, Inc., 6655 N. MacArthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: 1 March 201 1 (01 .03.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 61/274,124 1 March 2010 (01 .03.2010) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 61/357,5 17 22 June 2010 (22.06.2010) US ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/364,785 15 July 2010 (15.07.2010) us NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (71) Applicant (for all designated States except US): CARIS SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, LIFE SCIENCES LUXEMBOURG HOLDINGS [LU/ TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Approximately 15 Units of Penicillinase Were Preincubated with 4 Ml of Phenylisoxazolyl Penicillins (5 Mg/Ml) at 30°C
    INACTIVATION OF STAPHYLOCOCCAL PENICILLINASE BY DICLOXACILLIN Hitoshi Sagai and Tetsu Saito Research Laboratories, Toyo Jozo Co., Ltd. Ohito-cho, Shizuoka-ken, 410-23, Japan (Received for publication February 12, 1973) Staphylococcal penicillinase was inactivated by treatment with a relatively low concentration of methyldichlorophenyl-isoxazolyl penicillin (dicloxacillin). Inactivated enzyme was isolated by gel-filtration and reactivated by incubation at 37°C. It is suggested that the inactivated enzyme is penicilloyl enzyme which is readily hydrolyzed to active enzyme. The rates of hydrolysis of /3-lactamase-sensitive penicillins (such as benzylpenicillin and aminobenzylpenicillin) by penicillinase were greatly decreased by the addition of /3-lactamase resistant penicillins1'23. Gourevitch and his coworkers reported that the inactivation of cell-bound staphylococcal penicillinase occurred when the enzyme was preincubated with dimethoxyphenyl penicillin (methicillin), and the amount of inactivated enzyme corresponded to the amount of hydrolyzed methicillin3). On the other hand, Richmond demonstrated that the purified exo-enzyme of staphylococci degraded more than 85% of added methicillin without inactivation of the enzyme4). In this paper, we deal with the inactivation of the extracellular staphylococcal enzyme by dicloxacillin and propose a tentative mechanism to account for the inactivation. Materials and Methods Drugs : Benzylpenicillin potassium.salt, aminobenzylpenicillin (ampicillin) sodium salt, methyl- chlorophenylisoxazolyl penicillin (cloxacillin) sodium salt and dicloxacillin sodium salt (Toyo Jozo Co., Ltd.) were used. Organism: Staphylococcus aureus 0003 was used as the penicillinase source. The strain was of clincal origin and its penicillinase was inducible. Preparation of penicillinase: Partially purified enzyme was prepared according to the method reported by Richmond43. The supernatant fluid of methicillin-induced S.
    [Show full text]
  • Signal Transduction, Quorum-Sensing, and Extracellular Protease Activity in Enterococcus Faecalis Biofilm Formation
    Signal Transduction, Quorum-Sensing, and Extracellular Protease Activity in Enterococcus faecalis Biofilm Formation The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Carniol, K., and M. S. Gilmore. 2004. Signal Transduction, Quorum- Sensing, and Extracellular Protease Activity in Enterococcus Faecalis Biofilm Formation. Journal of Bacteriology 186, no. 24: 8161–8163. doi:10.1128/jb.186.24.8161-8163.2004. Published Version doi:10.1128/JB.186.24.8161-8163.2004 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33867369 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA JOURNAL OF BACTERIOLOGY, Dec. 2004, p. 8161–8163 Vol. 186, No. 24 0021-9193/04/$08.00ϩ0 DOI: 10.1128/JB.186.24.8161–8163.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. GUEST COMMENTARY Signal Transduction, Quorum-Sensing, and Extracellular Protease Activity in Enterococcus faecalis Biofilm Formation Karen Carniol1,2 and Michael S. Gilmore1,2* Department of Ophthalmology, Harvard Medical School,1 and The Schepens Eye Research Institute,2 Boston, Massachusetts Biofilms are surface-attached communities of bacteria, en- sponse regulator proteins (10). Only one of the mutants gen- cased in an extracellular matrix of secreted proteins, carbohy- erated, fsrA, impaired the ability of E. faecalis strain V583A to drates, and/or DNA, that assume phenotypes distinct from form biofilms in vitro.
    [Show full text]
  • Host and Bacterial Determinants of Staphylococcus Aureus Nasal Colonization in Humans
    University of Central Florida STARS Electronic Theses and Dissertations, 2004-2019 2014 Host and Bacterial Determinants of Staphylococcus aureus Nasal Colonization in Humans Gowrishankar Muthukrishnan University of Central Florida Part of the Medical Sciences Commons Find similar works at: https://stars.library.ucf.edu/etd University of Central Florida Libraries http://library.ucf.edu This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted for inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more information, please contact [email protected]. STARS Citation Muthukrishnan, Gowrishankar, "Host and Bacterial Determinants of Staphylococcus aureus Nasal Colonization in Humans" (2014). Electronic Theses and Dissertations, 2004-2019. 1289. https://stars.library.ucf.edu/etd/1289 HOST AND BACTERIAL DETERMINANTS OF STAPHYLOCOCCUS AUREUS NASAL COLONIZATION IN HUMANS by GOWRISHANKAR MUTHUKRISHNAN M.E. Birla Institute of Technology and Science, Pilani, India, 2007 M.S. University of Central Florida, United States of America, 2010 A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Burnett School of Biomedical Sciences in the College of Medicine at the University of Central Florida Orlando, Florida Summer Term 2014 Major Professor: Alexander M. Cole © 2014 Gowrishankar Muthukrishnan ii ABSTRACT Staphylococcus aureus (SA), an opportunistic pathogen colonizing the anterior nares in approximately 30% of the human population, causes severe hospital-associated and community-acquired infections. SA nasal carriage plays a critical role in the pathogenesis of staphylococcal infections and SA eradication from the nares has proven to be effective in reducing endogenous infections.
    [Show full text]